AMTX Aemetis

Aemetis Launches Aemetis Health Products Subsidiary

Aemetis Launches Aemetis Health Products Subsidiary

Company to offer Blended Liquid and Gel Hand Sanitizer as Bulk and Packaged Products

CUPERTINO, CA, Aug. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aemetis, Inc. (NASDAQ: AMTX) announced today the launch of its new Aemetis Health Products subsidiary which is focused on the production and marketing of blended liquid and gel sanitizers as bulk and packaged products.

“Aemetis has become the largest producer of high grade sanitizer alcohol in the western United States and is launching Aemetis Health Products to expand its product line of sanitizer products,” said Eric McAfee, Chairman and CEO of Aemetis.  “This expansion into blended liquid and gel sanitizer markets complements our existing offering of high grade alcohol in the United States and Canada.”

As a result of the global COVID-19 pandemic, demand for high grade alcohol for sanitizer production increased significantly in early 2020.   Aemetis Health Products will blend gel and liquid sanitizer for delivery in bulk as well as packaged form to customers. 

Aemetis is currently constructing plant upgrades of control systems and processing equipment that will enable the production of US Pharmacopeia (USP) medical grade alcohol at the Aemetis plant near Modesto, California.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe.  Aemetis is building a biogas anaerobic digester network and pipeline to convert dairy animal waste gas to Renewable Natural Gas (RNG), and is developing a plant to convert waste orchard wood into cellulosic ethanol.  Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals.  For additional information about Aemetis, please visit www..

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the construction and operation of the high grade alcohol production facility in Keyes, California, the receipt of US pharmacopeia certification, the and the ability to access markets and funding to execute our hand sanitizer business plan. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “will likely result,” “will continue”, “enable” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties.  Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2018, and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations

Contact:

Kirin Smith

PCG Advisory Group

(646) 863-6519

Company Investor Relations/

Media Contact:

Todd Waltz

 (408) 213-0940

EN
11/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aemetis

 PRESS RELEASE

Aemetis CEO Eric McAfee Receives Holmberg Award for Lifetime Achieveme...

Aemetis CEO Eric McAfee Receives Holmberg Award for Lifetime Achievement in the Bioeconomy CUPERTINO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a diversified renewable natural gas and biofuels company, announced that its CEO, Eric McAfee, was awarded the 2026 William C. Holmberg Memorial Award for Lifetime Achievement in the Bioeconomy. McAfee received the award and delivered the Holmberg Memorial Address acceptance speech during a ceremony on March 19, 2026, at the annual Advanced Biofuels Leadership Conference in Washington D.C., hosted by Biofuels Digest...

 PRESS RELEASE

Aemetis Reports Fourth Quarter and Full Year 2025 Results as Dairy RNG...

Aemetis Reports Fourth Quarter and Full Year 2025 Results as Dairy RNG Platform Scales Dairy RNG production increased 61% year over year in Q4 2025; ethanol plant efficiency upgrade expected to increase plant cash flow from operations by approximately $32 million annually Aemetis Biogas segment net income increased to $12.2 million in Q4 2025Aemetis Biogas segment increased annual revenues and production tax credits by 53%Dairy RNG production increased 61% year over year in Q4 2025Aemetis Biogas achieved annual segment net income of $6.9 millionCapital investments increased 28% over the pr...

 PRESS RELEASE

Aemetis to Review Fourth Quarter and Year End 2025 Financial Results o...

Aemetis to Review Fourth Quarter and Year End 2025 Financial Results on March 12, 2026 CUPERTINO, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its fourth quarter and year end 2025 earnings report: Date: Thursday, March 12, 2026 Time: 11 am Pacific Time (PT) Live Participant Dial In (Toll Free): entry code 452750 Live Participant Dial In (International): entry code 452750 Webcast URL: Attendees may submit questions during the Q&A (Questions & Answers) portion of the conferen...

 PRESS RELEASE

Aemetis India Subsidiary Begins Biodiesel Deliveries Under $24 Million...

Aemetis India Subsidiary Begins Biodiesel Deliveries Under $24 Million Allocation from OMCs CUPERTINO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a diversified renewable natural gas and biofuels company, announced that its Universal Biofuels subsidiary in India secured allocations of approximately $24 million for the supply of more than 27 million liters of biodiesel to India’s three government-owned Oil Marketing Companies (OMCs) for the period ending March 2026. Additional OMC fuel supply orders are expected throughout the year to support the India governme...

 PRESS RELEASE

Aemetis Receives Funds from the Sale of $17 million of Federal Clean E...

Aemetis Receives Funds from the Sale of $17 million of Federal Clean Energy Tax Credits CUPERTINO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable liquid fuels company focused on lower cost and reduced emissions products, today announced that its Aemetis Biogas LLC subsidiary received funds from the sale of $17 million of federal clean energy tax credits, including a Section 45Z Clean Fuel Production Credit (PTC) and a Section 48 Investment Tax Credit (ITC). The transaction included approximately $12 million for a Section 48 I...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch